NeuroBo submits IND application to FDA for Phase 1 trial of DA-1726

NeuroBo Pharmaceuticals announced that it has submitted an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA. The IND application supports a Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor, GLP1R, and glucagon receptor for the treatment of obesity. “Filing of the IND for DA-1726 is as a seminal event in the development of this GLP-1 and glucagon dual receptor, bringing it one step closer to the clinic as a potential new treatment to address the significant obesity market,” stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. “Preclinical evidence shows that DA-1726 reduced food intake while also increasing energy expenditure, which resulted in persistent weight loss in diet-induced obese mice and rats. Importantly, in mouse models, DA-1726 showed superior weight loss compared to semaglutide. Additionally, the administration of DA-1726 resulted in similar weight reduction while consuming more food compared to tirzepatide. It is our belief that DA-1726’s balanced activation between GLP-1 and glucagon receptors, may lead to better glycemic control and may have a better tolerability profile than current GLP-1 agonists. We look forward to initiating the clinical development for DA-1726, with the first dose expected to be administered in the first half of 2024 and an expected data readout in the first half of 2025.”